FIELD: medicine.
SUBSTANCE: methods of the invention involve introduction of (R)-3-[1-(2,6-dichlor-3-fluorophenyl)ethoxy]-5-(1-piperidine-4-yl-1H-pyrazole-4-yl)pyridine-2-ylamine (Compound 1) for treating the abnormal cell expansion and inhibition of activity of kinase s-Met/HGFR in a cell.
EFFECT: application of the inventions enables to inhibit growth of tumor ensured by inhibition of genetically changed kinases of receptor of hepatocyte and anaplastic lymphoma (ALK) growth factor with compound 1.
11 cl, 5 tbl, 11 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTIBODY TO c-Met | 2011 |
|
RU2607377C2 |
| CHIRAL DIARYL MACROCYCLES AND USE THEREOF | 2016 |
|
RU2728579C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY | 2009 |
|
RU2601892C2 |
| PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS | 2012 |
|
RU2598849C2 |
| HUMANISED ANTI c-met ANTAGONISTS | 2005 |
|
RU2398777C2 |
| SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2568258C2 |
| ANTIBODIES BOUND TO EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR (ALK) | 2007 |
|
RU2460540C2 |
| PROTEIN, METHOD OF PROTEIN PREPARING (VARIANTS), PHARMACEUTICAL COMPOSITION | 1992 |
|
RU2124024C1 |
| NEW CHEMICAL COMPOUNDS (VERSIONS) AND USING THEM FOR TREATING ONCOLOGICAL DISEASES | 2013 |
|
RU2550346C2 |
